PATENT CLAIM ANALYSIS

Application Number: 15755122
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "275000"]

Abstract:
The present disclosure relates to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.

Claim (Index 12):
The pharmaceutical combination according to  claim 1 , for use in the treatment or prevention of cancer.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 88.0
- Lexical Diversity: 1.56098
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13499779', '14197421', '14088598', '14893746', '12434963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8186478067752802
- 35 USC 102 Novelty (BERT): 0.5267216115727505
- Combined Prediction Score: 0.7894551872550272
- Mean Citation Score: 320.68665
- Max Citation Score: 344.15475
- Similarity Product: 251.50182034680245

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test